Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Interpace Diag Group (IDXG)

Interpace Diag Group (IDXG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,682
  • Shares Outstanding, K 3,820
  • Annual Sales, $ 21,900 K
  • Annual Income, $ -12,190 K
  • 60-Month Beta 2.05
  • Price/Sales 1.13
  • Price/Cash Flow N/A
  • Price/Book 1.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.75
  • Number of Estimates 2
  • High Estimate -0.50
  • Low Estimate -1.00
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.09 +17.77%
on 01/28/20
11.00 -24.09%
on 02/21/20
+1.28 (+18.02%)
since 01/27/20
3-Month
4.10 +103.56%
on 11/29/19
11.00 -24.09%
on 02/21/20
+4.00 (+92.09%)
since 11/27/19
52-Week
3.81 +119.16%
on 11/26/19
11.00 -24.09%
on 02/21/20
-0.85 (-9.24%)
since 02/27/19

Most Recent Stories

More News
Interpace Announces Extension of LabCorp Agreement

ThyGeNEXT and ThyraMIR Collaboration Extended for Another Two Years

IDXG : 8.35 (-8.04%)
LH : 182.59 (-0.55%)
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics' ThyraMIR miRNA classifier for...

IDXG : 8.35 (-8.04%)
Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership

-- Ron Rocca, CEO of Exagen, appointed to Board

IDXG : 8.35 (-8.04%)
XGN : 18.74 (+4.99%)
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners

Reverse Stock Split Planned Concurrent with Closing

IDXG : 8.35 (-8.04%)
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN(R) after Ablation of Dysplastic Barrett's Esophagus

Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company's wholly-owned subsidiary, Interpace Diagnostics has entered into a collaborative...

IDXG : 8.35 (-8.04%)
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT(R)

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company's ThyGeNEXT test,...

IDXG : 8.35 (-8.04%)
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China

Further Strengthens Business Development Team with Key Hire

IDXG : 8.35 (-8.04%)
Interpace Biosciences Launches New Corporate Website

Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, "Interpace.com". Now both the Diagnostics and Pharma Solutions businesses of Interpace are represented...

IDXG : 8.35 (-8.04%)
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results

Third Quarter Revenue Grew 34% Over the Prior Year's Quarter and 25% Year to Date

IDXG : 8.35 (-8.04%)
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019

Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss...

IDXG : 8.35 (-8.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade IDXG with:

Business Summary

Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey.

See More

Key Turning Points

2nd Resistance Point 9.21
1st Resistance Point 8.78
Last Price 8.35
1st Support Level 8.08
2nd Support Level 7.81

See More

52-Week High 11.00
Last Price 8.35
Fibonacci 61.8% 8.25
Fibonacci 50% 7.41
Fibonacci 38.2% 6.56
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar